Cargando…

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

BACKGROUND: Nivolumab monotherapy has demonstrated superior efficacy in advanced unresectable gastric cancer (GC), but its impact on resectable GC remains unknown. This phase I study aimed to evaluate safety, feasibility, and potential biomarkers of neoadjuvant nivolumab monotherapy in resectable GC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Hirotaka, Shitara, Kohei, Takiguchi, Shuji, Takiguchi, Noriaki, Ito, Seiji, Kochi, Mitsugu, Horinouchi, Hidehito, Kinoshita, Takahiro, Yoshikawa, Takaki, Muro, Kei, Nishikawa, Hiroyoshi, Suna, Hideaki, Kodera, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013329/ https://www.ncbi.nlm.nih.gov/pubmed/35254550 http://dx.doi.org/10.1007/s10120-022-01286-w

Ejemplares similares

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological Surgery
por: Tokunaga, Masanori, et al.
Publicado: (2023)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
por: Ishiwata, Tsukasa, et al.
Publicado: (2017)

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake
por: Ogata, Takatsugu, et al.
Publicado: (2020)

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
por: Higashiyama, Ryoko Inaba, et al.
Publicado: (2022)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Transformation of ActoHMM Assembly Confined in Cell-Sized Liposome
por: Takiguchi, Kingo, et al.
Publicado: (2011)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Indications for lateral lymph node dissection in patients with rectal neuroendocrine tumors: A case report and review of the literature
por: Fujii, Yoshiaki, et al.
Publicado: (2021)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors
por: Kawahara, Takashi, et al.
Publicado: (2022)

A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia
por: Yamamoto, Naoko, et al.
Publicado: (2019)

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
por: Nakaya, Seiichi, et al.
Publicado: (2021)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
por: Horinouchi, Hidehito
Publicado: (2016)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Effects of perioperative eicosapentaenoic acid-enriched oral nutritional supplement on the long-term oncological outcomes after total gastrectomy for gastric cancer
por: Aoyama, Toru, et al.
Publicado: (2022)

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report
por: Zang, Jing, et al.
Publicado: (2021)

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
por: Yoshida, Kazuhiro, et al.
Publicado: (2019)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer
por: Aoyama, Toru, et al.
Publicado: (2019)

Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
por: Master, Viraj A., et al.
Publicado: (2022)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
por: Dubus, Margaux, et al.
Publicado: (2023)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
por: Shitara, Kohei, et al.
Publicado: (2019)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)
por: Kawakami, Takeshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9bchui4va449p8m4877fbp4mik